Femasys (FEMY) AI Stock Analysis

• Market Cap: $25.92M
• Dividend Yield: N/A
• Average Volume (3M): 366.13K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.75
• Revenue Growth: 61.97%
• EPS Growth: -6.89%
• Country: US
• Employees: 69
• Sector: Healthcare
• Sector Strength: 58
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.23
• Shares Outstanding: 29,151,370
• 10 Day Avg. Volume: 571,083
• 30 Day Avg. Volume: 366,126
• PEG Ratio: -0.02
• Price to Book (P/B): 0.70
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.95
• Enterprise Value/Market Cap: -0.07
• Enterprise Value/Revenue: -0.32
• Enterprise Value/Gross Profit: -1.59
• Enterprise Value/Ebitda: 0.03
• 1Y Price Target: $7.00
• Price Target Upside: 686.52% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 38 Underperform
• Price Target: $1.00 ▲(12.36%Upside)

Femasys is experiencing significant financial challenges with ongoing losses and cash flow issues, reflected in a low financial performance score. Technical indicators support a bearish outlook, and valuation metrics suggest the stock is overvalued. The recent Nasdaq delisting notice further compounds these challenges, contributing to a low overall stock score.

Positive Factors

Market Expansion

FemaSeed is now being offered in more than 60 clinics across the U.S., which could allow for quick patient access.

Regulatory Approvals

FemBloc received EU approval, and the company announced partnerships in Spain, indicating international market expansion.

Strategic Partnerships

New partnership with CNY Fertility expands commercial footprint for FemaSeed, increasing revenue potential.

Negative Factors

Commercial Competition

Greater-than-expected commercial competition for any of the company’s programs, given other treatments on the market or in development.

Financial Performance

Overall sales in 1Q25 were $0.34M, which were much lower than our estimate of $1.5M.

Revenue Estimates

We have lowered our 2025 revenue based on the slower than expected ramp up, and now estimate revenues of $5.3M compared to our prior estimate of $10M.

Femasys Business Overview & Revenue Model

Company Description

Femasys Inc. (FEMY) is a biomedical company focused on advancing women's healthcare by developing innovative, non-surgical medical solutions. The company operates within the healthcare sector, specifically targeting the areas of reproductive health and infertility. Its core products include the FemVue Saline-Air device for fallopian tube assessment and FemBloc, a permanent contraceptive solution currently in development.

How the Company Makes Money

Femasys generates revenue primarily through the sale and distribution of its medical devices and technologies aimed at improving women's reproductive health. The company earns income from its flagship product, FemVue, which is utilized in clinical settings for diagnostic purposes. Additionally, as Femasys advances its product pipeline, regulatory approvals and successful commercialization of products like FemBloc are expected to become significant future revenue streams. Partnerships with healthcare providers and clinics further bolster its market presence and sales potential.

Femasys Financial Statement Overview

Summary

Femasys is facing financial headwinds with persistent losses and cash flow issues. Revenue growth is overshadowed by operational inefficiencies and financial instability. Improving financial health and achieving profitability are crucial for future sustainability.

Income Statement

Femasys has shown a slight increase in revenue over the years, but the company remains unprofitable with consistent negative EBIT and EBITDA margins. The net profit margin remains negative, and the revenue growth rate is volatile, suggesting challenges in achieving stable growth.

Balance Sheet

The balance sheet reflects financial instability with a negative equity position in earlier years, improving to positive but weak equity levels recently. The debt-to-equity ratio indicates high leverage, which could pose risks if not managed carefully. The company needs to strengthen its equity base for financial stability.

Cash Flow

Femasys consistently experiences negative operating and free cash flows, indicating operational challenges and a reliance on external financing. The cash flow to net income ratios are unfavorable, emphasizing the company's struggle to generate cash through operations.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.70M	1.63M	1.07M	1.21M	1.18M	1.04M
	Gross Profit
1.13M	1.08M	691.90K	764.28K	809.30K	731.38K
	EBIT
-19.78M	-17.79M	-14.51M	-11.60M	-8.34M	-6.93M
	EBITDA
-18.54M	-16.33M	-13.17M	-10.49M	-6.55M	-5.80M
	Net Income Common Stockholders
-21.11M	-18.82M	-14.25M	-11.39M	-7.54M	-6.91M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
0.00	3.45M	21.72M	12.96M	24.78M	3.32M
	Total Assets
0.00	12.45M	27.76M	16.90M	28.58M	7.61M
	Total Debt
7.67M	7.44M	6.70M	543.72K	990.21K	2.06M
	Net Debt
7.67M	3.99M	-15.02M	-12.42M	-23.79M	-1.27M
	Total Liabilities
1.44M	10.14M	9.40M	1.65M	2.24M	59.42M
	Stockholders Equity
2.00M	2.30M	18.35M	15.24M	26.33M	-51.82M
Cash Flow		Free Cash Flow
-20.50M	-20.21M	-11.42M	-11.14M	-8.24M	-4.96M
	Operating Cash Flow
-19.64M	-19.44M	-11.28M	-10.73M	-7.93M	-4.93M
	Investing Cash Flow
-854.21K	-847.76K	-143.92K	-407.48K	-306.87K	968.32K
	Financing Cash Flow
6.48M	2.03M	20.18M	-681.64K	29.70M	871.65K

Femasys Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.89
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FEMY, the sentiment is Negative. The current price of 0.89 is below the 20-day moving average (MA) of 0.93, below the 50-day MA of 1.06, and below the 200-day MA of 1.18, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 41.83 is Neutral, neither overbought nor oversold. The STOCH value of 75.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FEMY.

Femasys Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MHUA	66 Neutral	$12.04M	0.94	7.10%	―	-0.19%	-18.41%
Sector *	54 Neutral	$5.41B	3.27	-45.10%	3.29%	16.81%	0.02%
HBIO	53 Neutral	$23.14M	―	-138.80%	―	-14.41%	-549.88%
RVP	46 Neutral	$20.71M	―	-25.89%	―	-16.05%	-195.28%
MLSS	44 Neutral	$69.85M	―	-88.36%	―	-9.13%	30.04%
POAI	39 Underperform	$8.84M	―	-504.16%	―	-31.31%	49.27%
FEMY	38 Underperform	$25.92M	―	-239.87%	―	61.97%	-6.89%

Femasys Corporate Events

Femasys Announces Public Offering and Private Placement

On May 29, 2025, Femasys Inc. entered into an underwriting agreement with JonesTrading Institutional Services LLC for a public offering of 3,600,000 shares of common stock at $0.85 per share. The company also initiated a concurrent private placement with existing institutional stockholders and certain directors and officers, raising a total of approximately $4.5 million before expenses. The proceeds are intended for commercial expansion, product development, and general corporate purposes. Additionally, Femasys agreed to establish a $10 million equity line of credit with Alumni Capital LP by June 30, 2025, with potential penalties if not completed.

The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Femasys Receives Nasdaq Delisting Notice for Low Market Value

On May 19, 2025, Femasys received a notice from Nasdaq indicating that the market value of its listed securities had fallen below the required $35 million for continued listing on the Nasdaq Capital Market. The company has until November 17, 2025, to regain compliance, or it may face delisting. Femasys plans to actively monitor its market value and explore options to meet the requirement, although there is no assurance of success.

The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.